Edoxaban
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Edoxaban and local guidelines before prescribing.
Mechanism
Direct factor Xa inhibitor.
Uses
Stroke prevention in non-valvular AF, treatment and prevention of VTE.
Dosing
- Factor Xa inhibitors - apixaban (twice daily), rivaroxaban (once daily for AF - with food at 15 mg and 20 mg doses), edoxaban (once daily).
Haematology: Anatomy Physiology and Pharmacology - Edoxaban (Xa inhibitor) | 60 mg daily (30 mg if CrCl 15–50, weight 60 kg or less, or certain interacting drugs). After 5 days of LMWH for VTE
Haematology: Haemostasis and Thrombosis - Low body weight (under 50 kg) - reduce paracetamol (e.g. 15 mg/kg per dose; maximum per local guidance), DOAC dose criteria (apixaban - weight 60 kg or less is one criterion; edoxaban 60 kg or less), care with nephrotoxic and sedating drugs.
Clinical pharmacology and prescribing: Prescribing in special groups
Side effects
Bleeding, anaemia, rash, abnormal LFT.
Interactions
P-gp inhibitors raise levels; avoid with other anticoagulants.
Contraindications and cautions
Active bleeding, mechanical valve, severe liver disease
Monitoring
Renal function, Hb, weight
Pregnancy and breastfeeding
Avoid
Renal and hepatic impairment
Reduce dose if CrCl 15–50
Overdose and reversal
Andexanet alfa or prothrombin complex concentrate
Special advice
Dose reduce by weight, renal function and interacting drugs; reduced efficacy with CrCl above 95 in AF.
More from the textbook: uses, cautions and other points
- Where drugs act - aspirin (COX-1), clopidogrel/prasugrel/ticagrelor (P2Y12), warfarin (vitamin K-dependent factors II, VII, IX, X), heparins (antithrombin), apixaban/rivaroxaban/edoxaban (Xa), dabigatran (thrombin), alteplase/tenecteplase (plasminogen).
Cardiology: Anatomy Physiology and Pharmacology - Factor Xa inhibitors - apixaban (twice daily), rivaroxaban (once daily with food in AF), edoxaban (once daily).
Cardiology: Anatomy Physiology and Pharmacology - Lifelong warfarin (VKA) . DOACs (apixaban, rivaroxaban, dabigatran, edoxaban) must never be used - they caused excess valve thrombosis and stroke in trials.
Cardiology: Valvular heart disease › 4.34 Anticoagulation and Valves - Alternatives — LMWH for at least 5 days then dabigatran or edoxaban; or LMWH with warfarin (INR 2–3) until the INR is 2 or more for 2 days.
Cardiology: Venous Thromboembolism and Pulmonary Vascular Disease - Most patients: A DOAC - apixaban or rivaroxaban (no heparin lead-in needed), or LMWH then dabigatran or edoxaban.
Respiratory: Pulmonary Vascular Disease - Anticoagulation for AF-related stroke - a DOAC (apixaban, edoxaban, rivaroxaban, dabigatran) rather than aspirin; timing depends on stroke size (earlier start is increasingly used; follow current guidance). Never anticoagulate until haemorrhage has been excluded.
Neurology: Anatomy, Physiology and Pharmacology
Where it is discussed in the book
- Cardiology: Anatomy Physiology and Pharmacology (3 mentions)
- Cardiology: Valvular heart disease (1 mention)
- Cardiology: Venous Thromboembolism and Pulmonary Vascular Disease (1 mention)
- Respiratory: Pulmonary Vascular Disease (1 mention)
- Neurology: Anatomy, Physiology and Pharmacology (1 mention)
- Neurology: Stroke Emergencies (1 mention)
- Haematology: Anatomy Physiology and Pharmacology (2 mentions)
- Haematology: Haemostasis and Thrombosis (3 mentions)
- Oncology: Emergencies (1 mention)
- Surgery: Surgical principles and perioperative care (2 mentions)
- Clinical pharmacology and prescribing: Principles of clinical pharmacology (1 mention)
- Clinical pharmacology and prescribing: Prescribing in special groups (1 mention)
- Clinical pharmacology and prescribing: High-risk drugs, therapeutic drug monitoring, IV fluids and antimicrobial prescribing (1 mention)
- Acute Medicine: The acute medical take (1 mention)
- Anaesthesia: Preoperative assessment and principles of anaesthesia (1 mention)
- Integrated cardiology chapter (1 mention)
- Integrated respiratory chapter (1 mention)
- General Practice: Long-term conditions, multimorbidity and polypharmacy (1 mention)
- Pathology: Haemodynamic disorders, thrombosis, embolism and atherosclerosis (1 mention)